Immunotherapy-intensified paraneoplastic dermatomyositis

To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal an...

ver descrição completa

Detalhes bibliográficos
Autores: Estenaga, Á. (Ángela)|||/items/b25e8df1-8b45-48c6-b23b-a8574237d85e, Rodríguez-Garijo, N. (Nuria)|||/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62, Tomás-Velázquez, A. (Alejandra)|||/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205, Antoñanzas-Perez, J. (Javier)|||/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29, Álvarez-Gigli, L. (Laura)|||/items/a8dc006f-2621-4988-97d9-a5e9318f0731, Garcia-Tobar, L. (Laura)|||/items/64b398ed-0d60-4773-9118-e862d5d28ff9, España-Alonso, A. (Agustín)|||/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f, Salido-Vallejo, R. (Rafael)|||/items/358e939a-9001-4a19-a55d-f8dc95c53c34
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/116722
Acesso em linha:https://hdl.handle.net/10171/116722
Access Level:acceso abierto
Palavra-chave:Dermatomyositis
Immune checkpoint inhibitor
Immunotherapy
Complication
Treatment
Descrição
Resumo:To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal and skin symptoms after drug administration.

Registos relacionados